JMP Securities Upgrades BioCryst Pharma (BCRX) to Market Outperform
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $9.28 +1.53%
Rating Summary:
18 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 4 | Down: 13 | New: 23
Rating Summary:
18 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 4 | Down: 13 | New: 23
Join SI Premium – FREE
JMP Securities upgraded BioCryst Pharma (NASDAQ: BCRX) from Market Perform to Market Outperform with a price target of $3.00.
For an analyst ratings summary and ratings history on BioCryst Pharma click here. For more ratings news on BioCryst Pharma click here.
Shares of BioCryst Pharma closed at $2.04 yesterday.
For an analyst ratings summary and ratings history on BioCryst Pharma click here. For more ratings news on BioCryst Pharma click here.
Shares of BioCryst Pharma closed at $2.04 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wolfe Research Upgrades Target (TGT) to Outperform
- Morgan Stanley Upgrades QIAGEN NV (QIA:GR) (QGEN) to Overweight
- JPMorgan Upgrades IBM (IBM) to Overweight
Create E-mail Alert Related Categories
Hot Upgrades, UpgradesRelated Entities
JMP SecuritiesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
